Parathyroid Nodular Hyperplasia and Responsiveness to Drug Therapy in Renal Secondary Hyperparathyroidism: An Open Question. (Q48239717)

9 February 2018

title

Parathyroid Nodular Hyperplasia and Responsiveness to Drug Therapy in Renal Secondary Hyperparathyroidism: An Open Question. (English)

1 reference

9 February 2018

secondary hyperparathyroidism

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28980761%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Maurizio Bossola

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28980761%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Maurizio Bossola

series ordinal

2

1 reference

9 February 2018

publication date

5 October 2017

1 reference

9 February 2018

Therapeutic Apheresis and Dialysis

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28980761%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

22

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28980761%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

11-21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28980761%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28980761%20AND%20SRC:MED&resulttype=core&format=json

Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism

1 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Chronic kidney disease-mineral-bone disorder: a new paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Vascular calcification and renal osteodystrophy relationship in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Surgical treatment of secondary hyperparathyroidism due to chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Pathogenesis of refractory secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Parathyroid resistance to FGF23 in kidney transplant recipients: back to the past or ahead to the future?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Non-suppressible parathyroid hormone secretion is related to gland size in uremic secondary hyperparathyroidism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Depressed expression of calcium receptor in parathyroid gland tissue of patients with hyperparathyroidism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Surgical treatment of renal hyperparathyroidism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Parathyroid function in persistent hyperparathyroidism: relationship to gland size

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Relationship between parathyroid mass and parathyroid hormone level in hemodialysis patients with secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Management of Secondary Hyperparathyroidism: The Importance and the Challenge of Controlling Parathyroid Hormone Levels without Elevating Calcium, Phosphorus, and Calcium-Phosphorus Product

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Association of Drug Effects on Serum Parathyroid Hormone, Phosphorus, and Calcium Levels With Mortality in CKD: A Meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Cinacalcet versus standard treatment for chronic kidney disease: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Cinacalcet and Clinical Outcomes in Dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Utilization of parathyroidectomy for secondary hyperparathyroidism in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Impact of the Introduction of Calcimimetics on Timing of Parathyroidectomy in Secondary and Tertiary Hyperparathyroidism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Parathyroidectomy improves survival in patients with severe hyperparathyroidism: a comparative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Parathyroidectomy reduces cardiovascular events and mortality in renal hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Effect of parathyroidectomy on anemia and erythropoietin dosing in end-stage renal disease patients with hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Parathyroidectomy and heart rate variability in patients with stage 5 CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Optimizing the cost-effectiveness of treatment for chronic kidney disease-mineral and bone disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

An economic comparison of surgical and medical therapy in patients with secondary hyperparathyroidism--the German perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Cost-effectiveness of early versus late cinacalcet treatment in addition to standard care for secondary renal hyperparathyroidism in the USA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Reduction of functioning parathyroid cell mass by ethanol injection in chronic dialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

The Significance of Ultrasound in Determining Whether SHPT Patients Are Sensitive to Calcitriol Treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Switch from calcitriol to paricalcitol in secondary hyperparathyroidism of hemodialysis patients: Responsiveness is related to parathyroid gland size.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Is the volume of the parathyroid gland a predictor of Maxacalcitol response in advanced secondary hyperparathyroidism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Relationship between the dimension of parathyroid glands estimated by ultrasonography and the hyperplastic pattern in patients with renal hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Intravenous calcitriol therapy in an early stage prevents parathyroid gland growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Activation of calcium-sensing receptor accelerates apoptosis in hyperplastic parathyroid cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Cinacalcet HCl prevents development of parathyroid gland hyperplasia and reverses established parathyroid gland hyperplasia in a rodent model of CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Can cinacalcet replace parathyroid intervention in severe secondary hyperparathyroidism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Association of nodular hyperplasia with resistance to cinacalcet therapy for secondary hyperparathyroidism in hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Parathyroid gland ultrasound patterns and biochemical findings after one-year cinacalcet treatment for advanced secondary hyperparathyroidism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Two Years of Cinacalcet Hydrochloride Treatment Decreased Parathyroid Gland Volume and Serum Parathyroid Hormone Level in Hemodialysis Patients With Advanced Secondary Hyperparathyroidism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Diameter of parathyroid glands measured by computed tomography as a predictive indicator for response to cinacalcet in dialysis patients with secondary hyperparathyroidism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Cinacalcet upregulates calcium-sensing receptors of parathyroid glands in hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Histology and immunohistochemistry of the parathyroid glands in renal secondary hyperparathyroidism refractory to vitamin D or cinacalcet therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604

Cinacalcet induces apoptosis in parathyroid cells in patients with secondary hyperparathyroidism: histological and cytological analyses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2F1744-9987.12604